Lexicon Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
FMR LLC, through its subsidiaries, has reported beneficial ownership of 11.7% of Lexicon Pharmaceuticals Inc.'s common stock as of June 30, 2026.
NASDAQ
FMR LLC and Abigail P. Johnson have disclosed a combined beneficial ownership of 10.5% of Lexicon Pharmaceuticals Inc.'s common stock, totaling 38,137,535 shares, as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant Stake in Lexicon Pharmaceuticals
FMR LLC and its affiliates, along with Abigail P. Johnson, reported a continued beneficial ownership of 9.6% of Lexicon Pharmaceuticals Inc.'s common stock as of March 31, 2025.